Prof Constantine Tam
Honorary Clinical Professor
Department of Medicine
939 Scholarly works
7 Projects
HIGHLIGHTS
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Journal article
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
DOI: 10.1182/bloodadvances.20210056212022
Research grants (ARC, NHMRC, MRFF)
Understanding and Averting Blood Cancer Resistance to Therapy
2019
Research grants (ARC, NHMRC, MRFF)
The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
2017
Research Grant
Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
RECENT SCHOLARLY WORKS
2026
Journal article
First-line treatment for CLL in the era of targeted therapy
DOI: 10.1038/s41408-025-01434-22026
Journal article
Association between patient-reported symptoms and clinical outcomes in R/R CLL.
DOI: 10.1182/bloodadvances.20260204052026
Journal article
Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL.
DOI: 10.1002/ajh.705332026
Journal article
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study
DOI: 10.1016/j.cmi.2026.06.0192026
Journal article
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL
DOI: 10.1182/bloodadvances.20260216182026
Journal article
Risk-guided disease management to prevent heart failure in adult cancer survivors of previous cardiotoxic cancer treatments (REDEEM) trial
DOI: 10.1093/eurheartj/ehag785.38612026
Journal article
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma
DOI: 10.1111/bjh.707482026
Journal article
A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities
DOI: 10.1016/j.jtct.2026.05.027